SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
147 hedge funds and large institutions have $1.58B invested in SpringWorks Therapeutics in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 54 increasing their positions, 48 reducing their positions, and 11 closing their positions.
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
13% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 48
4% more funds holding
Funds holding: 142 → 147 (+5)
1.96% less ownership
Funds ownership: 111.38% → 109.42% (-2%)
13% less capital invested
Capital invested by funds: $1.82B → $1.58B (-$242M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
43% less call options, than puts
Call options by funds: $256K | Put options by funds: $453K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$17.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.88M |
| 3 |
Morgan Stanley
New York
|
+$5.12M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.88M |
| 5 |
BlackRock
New York
|
+$4.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$29.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$16M |
| 3 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
-$8.61M |
| 4 |
Goldman Sachs
New York
|
-$8.59M |
| 5 |
O
OrbiMed
New York
|
-$5.74M |
SWTX Hedge Fund Activity: Q3 2023 in Review
147 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q3 2023, worth a combined $1.58B — down 13% from $1.82B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new SWTX positions and 11 closed out — a net gain of 6 holders — while 54 added to existing stakes and 48 trimmed.
The largest buyer was Maverick Capital, opening a new position worth an estimated $17.4M. The largest seller was Bank of America, cutting an estimated $29.6M.
- 147 institutional investors held SpringWorks Therapeutics (SWTX) as of Q3 2023, up from 142 in Q2 2023.
- Funds reported $1.58B of SpringWorks Therapeutics stock for Q3 2023, down 13% quarter-over-quarter.
- 17 funds opened new SpringWorks Therapeutics positions in Q3 2023 and 11 closed out, a net change of +6 holders.
- The largest SpringWorks Therapeutics buyer in Q3 2023 was Maverick Capital, an estimated $17.4M added.
- The largest SpringWorks Therapeutics seller in Q3 2023 was Bank of America, an estimated $29.6M sold.
Based on aggregated 13F filings for Q3 2023.